Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 462

1.

Pooled Analysis of the Associations between Body Mass Index, Total Cholesterol, and Liver Cancer-related Mortality in Japan

Ukawa S, Tamakoshi A, Murakami Y, Kiyohara Y, Yamada M, Nagai M, Satoh A, Miura K, Ueshima H, Okamura T, EPOCH-JAPAN Research Group.

Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2089-2095.

2.

Prevalence of and risk factors for cerebral microbleeds in a general Japanese elderly community.

Yubi T, Hata J, Ohara T, Mukai N, Hirakawa Y, Yoshida D, Gotoh S, Hirabayashi N, Furuta Y, Ago T, Kitazono T, Kiyohara Y, Ninomiya T.

Neurol Clin Pract. 2018 Jun;8(3):223-231. doi: 10.1212/CPJ.0000000000000464.

PMID:
30105162
3.

Prevalence and Risk Factors for Polypoidal Choroidal Vasculopathy in a General Japanese Population: The Hisayama Study.

Fujiwara K, Yasuda M, Hata J, Oshima Y, Hashimoto S, Yoshitomi T, Kiyohara Y, Ishibashi T, Ninomiya T, Sonoda KH.

Semin Ophthalmol. 2018;33(6):813-819. doi: 10.1080/08820538.2018.1506483. Epub 2018 Aug 7.

PMID:
30084710
4.

Associations of Overweight, Obesity, and Underweight With High Serum Total Cholesterol Level Over 30 Years Among the Japanese Elderly: NIPPON DATA 80, 90, and 2010.

Shibata Y, Ojima T, Nakamura M, Kuwabara K, Miyagawa N, Saito Y, Nakamura Y, Kiyohara Y, Nakagawa H, Fujiyoshi A, Kadota A, Ohkubo T, Okamura T, Ueshima H, Okayama A, Miura K.

J Epidemiol. 2018 Jul 21. doi: 10.2188/jea.JE20170229. [Epub ahead of print]

5.

Serum 1,25-Dihydroxyvitamin D Level Is Inappropriate for Use in Prospective Studies of Cancer Incidence - Reply.

Umehara K, Mukai N, Kitazono T, Hoka S, Kiyohara Y, Ninomiya T.

Circ J. 2018 Jul 25;82(8):2216. doi: 10.1253/circj.CJ-17-0909. Epub 2018 Jul 11. No abstract available.

6.

Secular trends in the incidence, risk factors, and prognosis of transient ischemic attack in Japan: The Hisayama Study.

Furuta Y, Hata J, Mukai N, Hirakawa Y, Ago T, Kitazono T, Kiyohara Y, Ninomiya T.

Atherosclerosis. 2018 Jun;273:84-90. doi: 10.1016/j.atherosclerosis.2018.04.010. Epub 2018 Apr 12.

PMID:
29702429
7.

Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance.

Kiyohara Y, Uhara H, Ito Y, Matsumoto N, Tsuchida T, Yamazaki N.

J Dermatol. 2018 Apr;45(4):408-415. doi: 10.1111/1346-8138.14227. Epub 2018 Feb 20.

PMID:
29464755
8.

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.

Yamazaki N, Tsutsumida A, Takahashi A, Namikawa K, Yoshikawa S, Fujiwara Y, Kondo S, Mukaiyama A, Zhang F, Kiyohara Y.

J Dermatol. 2018 Apr;45(4):397-407. doi: 10.1111/1346-8138.14210. Epub 2018 Feb 5.

9.

Albuminuria Increases the Risks for Both Alzheimer Disease and Vascular Dementia in Community-Dwelling Japanese Elderly: The Hisayama Study.

Takae K, Hata J, Ohara T, Yoshida D, Shibata M, Mukai N, Hirakawa Y, Kishimoto H, Tsuruya K, Kitazono T, Kiyohara Y, Ninomiya T.

J Am Heart Assoc. 2018 Jan 20;7(2). pii: e006693. doi: 10.1161/JAHA.117.006693.

10.

Immune response-associated gene profiling in Japanese melanoma patients using multi-omics analysis.

Akiyama Y, Kiyohara Y, Yoshikawa S, Otsuka M, Kondou R, Nonomura C, Miyata H, Iizuka A, Ashizawa T, Ohshima K, Urakami K, Nagashima T, Kusuhara M, Sugino T, Yamaguchi K.

Oncol Rep. 2018 Mar;39(3):1125-1131. doi: 10.3892/or.2017.6173. Epub 2017 Dec 21.

PMID:
29286146
11.

Comparative profiling of cortical gene expression in Alzheimer's disease patients and mouse models demonstrates a link between amyloidosis and neuroinflammation.

Castillo E, Leon J, Mazzei G, Abolhassani N, Haruyama N, Saito T, Saido T, Hokama M, Iwaki T, Ohara T, Ninomiya T, Kiyohara Y, Sakumi K, LaFerla FM, Nakabeppu Y.

Sci Rep. 2017 Dec 19;7(1):17762. doi: 10.1038/s41598-017-17999-3.

12.

Nail apparatus melanoma in a Japanese population: a comparative study of surgical procedures and prognoses in a large series of 151 cases.

Ogata D, Uhara H, Tsutsumida A, Yamazaki N, Mochida K, Amano M, Yoshikawa S, Kiyohara Y, Tsuchida T.

Eur J Dermatol. 2017 Dec 1;27(6):620-626. doi: 10.1684/ejd.2017.3133.

PMID:
29165298
13.

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON).

Namikawa K, Tsutsumida A, Mizutani T, Shibata T, Takenouchi T, Yoshikawa S, Kiyohara Y, Uchi H, Furue M, Ogata D, Tsuchida T, Yamazaki N.

Jpn J Clin Oncol. 2017 Jul 1;47(7):664-667. doi: 10.1093/jjco/hyx063.

14.

Development and validation of a risk assessment tool for gastric cancer in a general Japanese population.

Iida M, Ikeda F, Hata J, Hirakawa Y, Ohara T, Mukai N, Yoshida D, Yonemoto K, Esaki M, Kitazono T, Kiyohara Y, Ninomiya T.

Gastric Cancer. 2018 May;21(3):383-390. doi: 10.1007/s10120-017-0768-8. Epub 2017 Oct 17.

PMID:
29043529
15.

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study.

Fujiwara Y, Yamazaki N, Kiyohara Y, Yoshikawa S, Yamamoto N, Tsutsumida A, Nokihara H, Namikawa K, Mukaiyama A, Zhang F, Tamura T.

Invest New Drugs. 2018 Apr;36(2):259-268. doi: 10.1007/s10637-017-0502-8. Epub 2017 Sep 7.

PMID:
28879519
16.

White-coat and masked hypertension are associated with albuminuria in a general population: the Hisayama Study.

Hata J, Fukuhara M, Sakata S, Arima H, Hirakawa Y, Yonemoto K, Mukai N, Kitazono T, Kiyohara Y, Ninomiya T.

Hypertens Res. 2017 Nov;40(11):937-943. doi: 10.1038/hr.2017.74. Epub 2017 Sep 7.

PMID:
28878300
17.

Day-to-Day Blood Pressure Variability and Risk of Dementia in a General Japanese Elderly Population: The Hisayama Study.

Oishi E, Ohara T, Sakata S, Fukuhara M, Hata J, Yoshida D, Shibata M, Ohtsubo T, Kitazono T, Kiyohara Y, Ninomiya T.

Circulation. 2017 Aug 8;136(6):516-525. doi: 10.1161/CIRCULATIONAHA.116.025667.

18.

The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.

Akiyama Y, Nonomura C, Ashizawa T, Iizuka A, Kondou R, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Asai A, Ito M, Kiyohara Y, Yamaguchi K.

Immunol Lett. 2017 Oct;190:20-25. doi: 10.1016/j.imlet.2017.07.005. Epub 2017 Jul 15.

PMID:
28716484
19.

Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan.

Uhara H, Kiyohara Y, Tsuda A, Takata M, Yamazaki N.

Clin Transl Oncol. 2018 Feb;20(2):169-175. doi: 10.1007/s12094-017-1706-2. Epub 2017 Jul 3.

20.

The ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cancer death in a Japanese community: The Hisayama Study.

Nagata M, Hata J, Hirakawa Y, Mukai N, Yoshida D, Ohara T, Kishimoto H, Kawano H, Kitazono T, Kiyohara Y, Ninomiya T.

J Epidemiol. 2017 Dec;27(12):578-583. doi: 10.1016/j.je.2017.01.004. Epub 2017 Jun 29.

21.

Morning and Evening Blood Pressures Are Associated With Intima-Media Thickness in a General Population - The Hisayama Study.

Sakata S, Hata J, Fukuhara M, Yonemoto K, Mukai N, Yoshida D, Kishimoto H, Ohtsubo T, Kitazono T, Kiyohara Y, Ninomiya T.

Circ J. 2017 Oct 25;81(11):1647-1653. doi: 10.1253/circj.CJ-16-1306. Epub 2017 Jun 14.

22.

Alternative Measures of Hyperglycemia and Risk of Alzheimer's Disease in the Community: The Hisayama Study.

Mukai N, Ohara T, Hata J, Hirakawa Y, Yoshida D, Kishimoto H, Koga M, Nakamura U, Kitazono T, Kiyohara Y, Ninomiya T.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):3002-3010. doi: 10.1210/jc.2017-00439.

PMID:
28605542
23.

Association of Airflow Limitation With Carotid Atherosclerosis in a Japanese Community - The Hisayama Study.

Kudo K, Hata J, Matsumoto K, Shundo Y, Fukuyama S, Inoue H, Kitazono T, Kiyohara Y, Ninomiya T, Nakanishi Y.

Circ J. 2017 Nov 24;81(12):1846-1853. doi: 10.1253/circj.CJ-16-1305. Epub 2017 Jun 6.

24.

Erratum to "Characteristics and prognosis of Japanese colorectal cancer patients: The BioBank Japan Project" [J Epidemiol 27(3S) (2017) S36-S42].

Tamakoshi A, Nakamura K, Ukawa S, Okada E, Hirata M, Nagai A, Matsuda K, Kamatani Y, Muto K, Kiyohara Y, Yamagata Z, Ninomiya T, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group.

J Epidemiol. 2017 Aug;27(8):398-399. doi: 10.1016/j.je.2017.04.001. Epub 2017 Jun 5. No abstract available.

25.

Development of a self-scored persistent airflow obstruction screening questionnaire in a general Japanese population: the Hisayama study.

Samukawa T, Matsumoto K, Tsukuya G, Koriyama C, Fukuyama S, Uchida A, Mizuno K, Miyahara H, Kiyohara Y, Ninomiya T, Inoue H.

Int J Chron Obstruct Pulmon Dis. 2017 May 15;12:1469-1481. doi: 10.2147/COPD.S130453. eCollection 2017.

26.

Dietary Protein Intake and Stroke Risk in a General Japanese Population: The Hisayama Study.

Ozawa M, Yoshida D, Hata J, Ohara T, Mukai N, Shibata M, Uchida K, Nagata M, Kitazono T, Kiyohara Y, Ninomiya T.

Stroke. 2017 Jun;48(6):1478-1486. doi: 10.1161/STROKEAHA.116.016059. Epub 2017 May 9.

PMID:
28487340
27.

Melanoma patient response to nivolumab treatment for metastatic lung lesions: Multi-OMICS analysis in Project HOPE.

Kiyohara Y, Yoshikawa S, Otsuka M, Kondou R, Iizuka A, Nonomura C, Ohshima K, Urakami K, Kusuhara M, Nagashima T, Sugino T, Yamaguchi K, Akiyama Y.

J Dermatol. 2017 Oct;44(10):1156-1159. doi: 10.1111/1346-8138.13879. Epub 2017 Apr 28.

PMID:
28452169
28.

Association Between Serum Vitamin D and All-Cause and Cause-Specific Death in a General Japanese Population - The Hisayama Study.

Umehara K, Mukai N, Hata J, Hirakawa Y, Ohara T, Yoshida D, Kishimoto H, Kitazono T, Hoka S, Kiyohara Y, Ninomiya T.

Circ J. 2017 Aug 25;81(9):1315-1321. doi: 10.1253/circj.CJ-16-0954. Epub 2017 Apr 20.

29.

Trends in dementia prevalence, incidence, and survival rate in a Japanese community.

Ohara T, Hata J, Yoshida D, Mukai N, Nagata M, Iwaki T, Kitazono T, Kanba S, Kiyohara Y, Ninomiya T.

Neurology. 2017 May 16;88(20):1925-1932. doi: 10.1212/WNL.0000000000003932. Epub 2017 Apr 19.

PMID:
28424272
30.

Retrospective evaluation of factors influencing successful skin grafting for patients with skin cancer of the foot.

Goto H, Yoshikawa S, Mori K, Otsuka M, Omodaka T, Yoshimi K, Yoshida Y, Yamamoto O, Kiyohara Y.

J Dermatol. 2017 Sep;44(9):1043-1045. doi: 10.1111/1346-8138.13866. Epub 2017 Apr 13.

PMID:
28407348
31.

Differential diagnosis of trabectedin extravasation: A case report.

Yoshimi K, Wasa J, Otsuka M, Yoshikawa S, Goto H, Omodaka T, Katagiri H, Murata H, Hosaka S, Kiyohara Y.

J Dermatol. 2017 Aug;44(8):e200-e201. doi: 10.1111/1346-8138.13854. Epub 2017 Apr 9. No abstract available.

PMID:
28391600
32.

Fasting but not casual blood glucose is associated with pancreatic cancer mortality in Japanese: EPOCH-JAPAN.

Nagai M, Murakami Y, Tamakoshi A, Kiyohara Y, Yamada M, Ukawa S, Hirata T, Tanaka S, Miura K, Ueshima H, Okamura T; Evidence for Cardiovascular Prevention from Observational Cohorts in Japan (EPOCH-JAPAN) Research Group.

Cancer Causes Control. 2017 Jun;28(6):625-633. doi: 10.1007/s10552-017-0884-0. Epub 2017 Mar 28.

PMID:
28352981
33.

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study.

Yamazaki N, Kiyohara Y, Uhara H, Uehara J, Fujimoto M, Takenouchi T, Otsuka M, Uchi H, Ihn H, Minami H.

Cancer Sci. 2017 Jun;108(6):1223-1230. doi: 10.1111/cas.13241. Epub 2017 Jun 15.

34.

Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.

Yoshikawa S, Kiyohara Y, Otsuka M, Kondou R, Nonomura C, Miyata H, Iizuka A, Ohshima K, Urakami K, Nagashima T, Kusuhara M, Sugino T, Mochizuki T, Yamaguchi K, Akiyama Y.

Anticancer Res. 2017 Mar;37(3):1321-1328.

PMID:
28314298
35.

Translocation of the MAML2 gene in hidradenocarcinoma.

Yoshimi K, Goto H, Otsuka M, Yoshikawa S, Omodaka T, Kiyohara Y.

J Dermatol. 2017 Aug;44(8):e190-e191. doi: 10.1111/1346-8138.13830. Epub 2017 Mar 11. No abstract available.

PMID:
28295544
36.

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).

Yamazaki N, Takenouchi T, Fujimoto M, Ihn H, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Wada H, Noguchi K, Shimamoto T, Yokota K.

Cancer Chemother Pharmacol. 2017 Apr;79(4):651-660. doi: 10.1007/s00280-016-3237-x. Epub 2017 Mar 11.

37.

Determinants of Glycated Hemoglobin in Subjects With Impaired Glucose Tolerance: Subanalysis of the Japan Diabetes Prevention Program.

Sakane N, Sato J, Tsushita K, Tsujii S, Kotani K, Tominaga M, Kawazu S, Sato Y, Usui T, Kamae I, Yoshida T, Kiyohara Y, Sato S, Tsuzaki K, Nirengi S, Takahashi K, Kuzuya H, Group JR.

J Clin Med Res. 2017 Apr;9(4):360-365. doi: 10.14740/jocmr2928w. Epub 2017 Feb 21.

38.

Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma.

Yamazaki N, Kiyohara Y, Uhara H, Iizuka H, Uehara J, Otsuka F, Fujisawa Y, Takenouchi T, Isei T, Iwatsuki K, Uchi H, Ihn H, Minami H, Tahara H.

Cancer Sci. 2017 May;108(5):1022-1031. doi: 10.1111/cas.13226. Epub 2017 May 11.

39.

Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project.

Nakamura K, Okada E, Ukawa S, Hirata M, Nagai A, Yamagata Z, Kiyohara Y, Muto K, Kamatani Y, Ninomiya T, Matsuda K, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group, Tamakoshi A.

J Epidemiol. 2017 Mar;27(3S):S58-S64. doi: 10.1016/j.je.2016.12.009. Epub 2017 Feb 20.

40.

Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project.

Ukawa S, Nakamura K, Okada E, Hirata M, Nagai A, Yamagata Z, Muto K, Matsuda K, Ninomiya T, Kiyohara Y, Kamatani Y, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group, Tamakoshi A.

J Epidemiol. 2017 Mar;27(3S):S65-S70. doi: 10.1016/j.je.2016.12.008. Epub 2017 Feb 17.

41.

Characteristics and prognosis of Japanese colorectal cancer patients: The BioBank Japan Project.

Tamakoshi A, Nakamura K, Ukawa S, Okada E, Hirata M, Nagai A, Matsuda K, Kamatani Y, Muto K, Kiyohara Y, Yamagata Z, Ninomiya T, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group.

J Epidemiol. 2017 Mar;27(3S):S36-S42. doi: 10.1016/j.je.2016.12.004. Epub 2017 Feb 15. Erratum in: J Epidemiol. 2017 Aug;27(8):398-399.

42.

Characteristics of patients with liver cancer in the BioBank Japan project.

Ukawa S, Okada E, Nakamura K, Hirata M, Nagai A, Matsuda K, Yamagata Z, Kamatani Y, Ninomiya T, Kiyohara Y, Muto K, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group, Tamakoshi A.

J Epidemiol. 2017 Mar;27(3S):S43-S48. doi: 10.1016/j.je.2016.12.007. Epub 2017 Feb 15.

43.

Survival of macrovascular disease, chronic kidney disease, chronic respiratory disease, cancer and smoking in patients with type 2 diabetes: BioBank Japan cohort.

Yokomichi H, Nagai A, Hirata M, Kiyohara Y, Muto K, Ninomiya T, Matsuda K, Kamatani Y, Tamakoshi A, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group, Yamagata Z.

J Epidemiol. 2017 Mar;27(3S):S98-S106. doi: 10.1016/j.je.2016.12.012. Epub 2017 Feb 10.

44.

Characteristics and prognosis of Japanese male and female lung cancer patients: The BioBank Japan Project.

Nakamura K, Ukawa S, Okada E, Hirata M, Nagai A, Yamagata Z, Ninomiya T, Muto K, Kiyohara Y, Matsuda K, Kamatani Y, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group, Tamakoshi A.

J Epidemiol. 2017 Mar;27(3S):S49-S57. doi: 10.1016/j.je.2016.12.010. Epub 2017 Feb 13.

45.

Cholesterol levels of Japanese dyslipidaemic patients with various comorbidities: BioBank Japan.

Yokomichi H, Noda H, Nagai A, Hirata M, Tamakoshi A, Kamatani Y, Kiyohara Y, Matsuda K, Muto K, Ninomiya T, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group, Yamagata Z.

J Epidemiol. 2017 Mar;27(3S):S77-S83. doi: 10.1016/j.je.2016.12.014. Epub 2017 Feb 11.

46.

Statin use and all-cause and cancer mortality: BioBank Japan cohort.

Yokomichi H, Nagai A, Hirata M, Tamakoshi A, Kiyohara Y, Kamatani Y, Muto K, Ninomiya T, Matsuda K, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group, Yamagata Z.

J Epidemiol. 2017 Mar;27(3S):S84-S91. doi: 10.1016/j.je.2016.12.011. Epub 2017 Feb 11.

47.

Overview of BioBank Japan follow-up data in 32 diseases.

Hirata M, Nagai A, Kamatani Y, Ninomiya T, Tamakoshi A, Yamagata Z, Kubo M, Muto K, Kiyohara Y, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H, Tanaka T, Ohnishi Y, Nakamura Y; BioBank Japan Cooperative Hospital Group, Matsuda K.

J Epidemiol. 2017 Mar;27(3S):S22-S28. doi: 10.1016/j.je.2016.12.006. Epub 2017 Feb 10. Review.

48.

Demographic and lifestyle factors and survival among patients with esophageal and gastric cancer: The Biobank Japan Project.

Okada E, Ukawa S, Nakamura K, Hirata M, Nagai A, Matsuda K, Ninomiya T, Kiyohara Y, Muto K, Kamatani Y, Yamagata Z, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group, Tamakoshi A.

J Epidemiol. 2017 Mar;27(3S):S29-S35. doi: 10.1016/j.je.2016.12.002. Epub 2017 Feb 9.

49.

Cross-sectional analysis of BioBank Japan clinical data: A large cohort of 200,000 patients with 47 common diseases.

Hirata M, Kamatani Y, Nagai A, Kiyohara Y, Ninomiya T, Tamakoshi A, Yamagata Z, Kubo M, Muto K, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H, Tanaka T, Ohnishi Y, Nakamura Y; BioBank Japan Cooperative Hospital Group, Matsuda K.

J Epidemiol. 2017 Mar;27(3S):S9-S21. doi: 10.1016/j.je.2016.12.003. Epub 2017 Feb 9.

50.

Overview of the BioBank Japan Project: Study design and profile.

Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, Ninomiya T, Tamakoshi A, Yamagata Z, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H, Tanaka T, Ohnishi Y, Nakamura Y; BioBank Japan Cooperative Hospital Group, Kubo M.

J Epidemiol. 2017 Mar;27(3S):S2-S8. doi: 10.1016/j.je.2016.12.005. Epub 2017 Feb 8. Review.

Supplemental Content

Loading ...
Support Center